Overview
Pfizer is a research-based biopharmaceutical company headquartered in New York that discovers, develops, manufactures and distributes medicines and vaccines worldwide; Forbes dates it to 1849, when it was founded by Charles Pfizer Sr. and Charles Erhart.[2] Its Forbes sales of US$63.3bn were almost unchanged from the prior-year figure of US$63.6bn, and profit was US$7.5bn.[2] Pfizer has used acquisitions to add new growth areas. In November 2025 it completed the purchase of Metsera for US$65.60 per share in cash, an enterprise value of about US$7.0bn, plus a contingent value right worth up to US$20.65 per share; the main asset is MET-097i, an injectable GLP-1 receptor agonist about to enter Phase 3.[4] The deal gives Pfizer a candidate in the obesity market, where Lilly and Novo Nordisk already sell medicines. Forbes puts its workforce at 75,000.[2]
Pfizer strengths and limitations
Strengths
- Fifth-largest sales
- Large vaccine and anti-infective business
- Entering obesity through the Metsera acquisition
Limitations
- Sales fell 0.5% against the prior-year figure
- Obesity assets are still in development
- Metsera deal expected to dilute earnings for several years
Appears in
Pfizer peers and competitors
Companies ranked in the same lists as Pfizer.
Johnson & Johnson
Takeda Pharmaceutical
Daiichi Sankyo- Astellas Pharma
Viatris- Regeneron Pharmaceuticals
- CSL
Otsuka Holdings- Teva Pharmaceutical
Merck KGaA
Gilead Sciences- Amgen
Is this your company?
Update the description, logo, image and link through the submission form. Editors review every change.